EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B






Journal of Infection 22(1): 45-52

The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B

In a randomised clinical trial, we compared the efficacy of the new triazole drug itraconazole (200 mg orally twice daily) with that of amphotericin B (0.6 mg/kg daily or 0.3 mg/kg in combination with flucytosine) in neutropenic (less than 500 x 10(6)/l neutrophils) patients with proven or highly suspected systemic fungal infections. Patients with unexplained fever alone were not included in the study. Of the 40 patients enrolled, 32 patients (16 males, 16 females) were evaluable. Sixteen patients (median age 49 years) were treated with itraconazole for a median period of 20 days and 16 patients (median age 32 years) received amphotericin B for a median period of 13 days. The overall clinical response was 10/16 (63%) for patients treated with itraconazole and 9/16 (56%) for patients treated with amphotericin B (P greater than 0.90). Itraconazole seemed to be more effective against Aspergillus infections, whereas amphotericin B seemed to be more effective against candidal infections, although the differences were not statistically significant.

Accession: 002249703

PMID: 1848268

DOI: 10.1016/0163-4453(91)90954-q

Download PDF Full Text: The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B



Related references

Treatment of systemic mycoses in neutropenic patients with itraconazole. A comparative, randomised study with amphotericin B. Medizinische Klinik 86(Suppl. 1): 11-13, 1991

Open label, randomised, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infection. Journal of the Association of Physicians of India 50(5): 662-670, 2002

Therapy of systemic mycoses in neutropenic patients using itraconazole. A comparative, randomized study with amphotericin B. Medizinische Klinik 86 Suppl 1: 11-13, 1991

Amphotericin B followed by itraconazole in the treatment of disseminated fungal infections in neutropenic patients. Mycoses 37(11-12): 433-437, 1994

Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. Journal of Antimicrobial ChemoTherapy 48(1): 97-103, 2001

An open, non-comparative evaluation of the efficacy and safety of amphotericin B lipid complex as treatment of neutropenic patients with presumed or confirmed pulmonary fungal infections. Journal of Antimicrobial ChemoTherapy 41(3): 424-426, 1998

Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients. Netherlands Journal of Medicine 39(1-2): 84-91, 1991

Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leukemia & Lymphoma 11(5-6): 353-358, 1993

Economic evaluation of intravenous itraconazole for presumed systemic fungal infections in neutropenic patients in Korea. International Journal of Hematology 82(3): 251-258, 2005

Prophylactic administration of intravenous amphotericin b does not prevent systemic fungal infections in neutropenic patients with acute leukemia. Onkologie 14(SUPPL 2): 5, 1991